Tonix Pharmaceuticals Q4 EPS $(0.86) Beats $(1.55) Estimate, Sales $3.80M Miss $5.75M Estimate
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals reported Q4 earnings with losses of $(0.86) per share, surpassing the $(1.55) estimate, marking a 75.43% improvement from last year. However, their sales of $3.80M fell short of the $5.75M estimate.
April 01, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Tonix Pharmaceuticals reported a smaller than expected Q4 loss per share but missed sales estimates.
While the better than expected loss per share could be seen positively, the miss on sales estimates may raise concerns about revenue growth and operational efficiency. The mixed results present a neutral outlook in the short term as investors weigh the improved loss per share against the missed sales expectations.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100